Dingwei Ye

10.1k total citations · 6 hit papers
135 papers, 5.0k citations indexed

About

Dingwei Ye is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Dingwei Ye has authored 135 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Pulmonary and Respiratory Medicine, 56 papers in Oncology and 31 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Dingwei Ye's work include Prostate Cancer Treatment and Research (75 papers), Prostate Cancer Diagnosis and Treatment (33 papers) and Renal cell carcinoma treatment (30 papers). Dingwei Ye is often cited by papers focused on Prostate Cancer Treatment and Research (75 papers), Prostate Cancer Diagnosis and Treatment (33 papers) and Renal cell carcinoma treatment (30 papers). Dingwei Ye collaborates with scholars based in China, United States and Japan. Dingwei Ye's co-authors include Kim N., Mustafa Özgüroğlu, Karim Fizazi, Luis Fein, Susan Feyerabend, Nobuaki Matsubara, Andrew Protheroe, B. Yа. Alekseev, A. Rodrı́guez-Antolı́n and Peter De Porre and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Dingwei Ye

127 papers receiving 5.0k citations

Hit Papers

Abiraterone plus Prednisone in Metastatic, Castration-Sen... 2016 2026 2019 2022 2017 2019 2019 2021 2016 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
    2017 1.4k citations Mustafa Özgüroğlu, Dingwei Ye et al. profile →
  2. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
    2019 891 citations Kim N., Neeraj Agarwal et al. profile →
  3. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
    2019 517 citations Mustafa Özgüroğlu, Dingwei Ye et al. profile →
  4. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
    2021 285 citations Kim N., Simon Chowdhury et al. Journal of Clinical Oncology profile →
  5. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
    2016 261 citations Shahrokh F. Shariat, Dingwei Ye et al. profile →
  6. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
    2023 99 citations Dingwei Ye, Hiroyoshi Suzuki et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dingwei Ye China 26 3.9k 1.6k 1.3k 1.1k 958 135 5.0k
Simon Chowdhury United Kingdom 29 4.0k 1.0× 1.4k 0.9× 1.3k 1.0× 1.4k 1.3× 1.0k 1.1× 199 5.1k
Matthew M. Cooney United States 24 3.6k 0.9× 1.1k 0.7× 1.1k 0.9× 1.8k 1.7× 1.0k 1.1× 86 5.2k
Nobuaki Matsubara Japan 28 3.5k 0.9× 1.1k 0.7× 1.4k 1.1× 2.3k 2.2× 878 0.9× 233 5.6k
Susan Feyerabend United Kingdom 21 3.2k 0.8× 1.1k 0.7× 1.0k 0.8× 1.0k 1.0× 726 0.8× 71 3.9k
Peter De Porre United States 26 2.5k 0.6× 854 0.5× 893 0.7× 761 0.7× 730 0.8× 91 3.4k
Mohammad Hirmand United States 18 4.6k 1.2× 1.6k 1.0× 1.6k 1.3× 1.3k 1.3× 1.2k 1.2× 38 5.2k
J Horti Hungary 9 3.6k 0.9× 1.1k 0.7× 1.2k 0.9× 1.6k 1.5× 1.0k 1.1× 17 4.6k
William R. Berry United States 11 3.9k 1.0× 1.1k 0.7× 1.3k 1.0× 1.8k 1.7× 985 1.0× 22 4.9k
Aude Fléchon France 33 4.9k 1.3× 1.5k 0.9× 1.6k 1.2× 2.6k 2.5× 1.8k 1.9× 273 7.7k
Evan Y. Yu United States 40 3.2k 0.8× 1.2k 0.8× 1.0k 0.8× 2.4k 2.3× 1.4k 1.5× 294 5.9k

Countries citing papers authored by Dingwei Ye

Since Specialization
Citations

This map shows the geographic impact of Dingwei Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dingwei Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dingwei Ye more than expected).

Fields of papers citing papers by Dingwei Ye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dingwei Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dingwei Ye. The network helps show where Dingwei Ye may publish in the future.

Co-authorship network of co-authors of Dingwei Ye

This figure shows the co-authorship network connecting the top 25 collaborators of Dingwei Ye. A scholar is included among the top collaborators of Dingwei Ye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dingwei Ye. Dingwei Ye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Linhui, Yuelong Li, Liqing Li, et al.. (2025). Detection, molecular function and mechanisms of m5C in cancer. Clinical and Translational Medicine. 15(3). e70239–e70239. 5 indexed citations
2.
Wang, Hongkai, Dalong Cao, Márcio Covas Moschovas, et al.. (2025). Early clinical experience with the Carina robotic platform in urologic surgery. BJUI Compass. 6(7). e70050–e70050. 1 indexed citations
3.
Galsky, Matthew D., Dean F. Bajorin, Yoshihiko Tomita, et al.. (2025). Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial. Nature Medicine. 31(9). 3062–3073.
4.
Jin, Shengming, et al.. (2025). Comprehensive analysis of the LINC01122/TPD52 axis as a predictive biomarker in prostate adenocarcinoma. Scientific Reports. 15(1). 16122–16122.
5.
Pan, Jian, Junlong Wu, Bin Zhu, et al.. (2024). Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer. Med. 5(12). 1475–1484.e3. 5 indexed citations
6.
Xu, Wenhao, Xi Tian, Shiqi Ye, et al.. (2024). Unveiling the impact of tertiary lymphoid structures on immunotherapeutic responses of clear cell renal cell carcinoma. SHILAP Revista de lepidopterología. 5(1). e461–e461. 27 indexed citations
7.
8.
Yu, Wei, Jian Pan, Shengming Jin, et al.. (2023). Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity. Molecular Oncology. 17(10). 2183–2199. 6 indexed citations
9.
Chang, Kun, Yingji Chen, Wei Zhang, et al.. (2023). DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma. Cancer Research. 83(23). 3940–3955. 66 indexed citations
10.
Sun, Rui, Binyuan Yan, Hao Li, et al.. (2023). Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis. Cancer Research. 83(19). 3192–3204. 25 indexed citations
11.
Chung, Byung Ha, Jian Huang, Hiroji Uemura, et al.. (2023). Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial. Asian Journal of Andrology. 25(6). 653–661. 3 indexed citations
12.
13.
Bajorin, Dean F., J. Alfred Witjes, Jürgen E. Gschwend, et al.. (2021). First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).. Journal of Clinical Oncology. 39(6_suppl). 391–391. 30 indexed citations
14.
N., Kim, Simon Chowdhury, Anders Bjartell, et al.. (2021). Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. Journal of Clinical Oncology. 39(20). 2294–2303. 285 indexed citations breakdown →
15.
16.
Yang, Yunjie, Bo Dai, Dingwei Ye, Yunyi Kong, & Gao‐xiang Li. (2019). The predictive value of CTCs characterization for time to castration resistance of high-volume metastatic castration sensitive prostate cancer. Zhonghua miniao waike zazhi. 40(9). 661–667. 1 indexed citations
17.
Liu, Yanfang, Hirotsugu Uemura, Dingwei Ye, et al.. (2018). Prostate cancer in Asia: design of a patient registry to inform real-world treatments, outcomes, and quality of life. Prostate International. 7(3). 108–113. 11 indexed citations
18.
Xu, Xiaoping, Yao Zhu, Hengchuan Su, et al.. (2016). Preliminary clinical study of (99m)Tc-labelled small molecules against PSMA for prostate cancer imaging. Zhongguo aizheng zazhi. 26(7). 608–615. 1 indexed citations
19.
Ye, Dingwei & Yao Zhu. (2015). [Epidemiology of prostate cancer in China: an overview and clinical implication].. PubMed. 53(4). 249–52. 34 indexed citations
20.
Zhang, Guiming, Yao Zhu, Haitao Chen, et al.. (2015). Association Between the Body Mass Index and Prostate Cancer at Biopsy is Modified by Genetic Risk. Medicine. 94(42). e1603–e1603. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Simon Chowdhury Breakdown of academic impact, for papers by Matthew M. Cooney Breakdown of academic impact, for papers by Nobuaki Matsubara Breakdown of academic impact, for papers by Susan Feyerabend Breakdown of academic impact, for papers by Peter De Porre Breakdown of academic impact, for papers by Mohammad Hirmand Breakdown of academic impact, for papers by J Horti Breakdown of academic impact, for papers by William R. Berry Breakdown of academic impact, for papers by Aude Fléchon Breakdown of academic impact, for papers by Evan Y. Yu
Rankless by CCL
2026